It is becoming increasingly clear that there are unique sets of miRNAs that have distinct governing roles in several aspects of both innate and adaptive immune responses. In addition, new tools allow selective modulation of the expression of individual miRNAs, both in vitro and in vivo. Here, we summarize recent advances in our understanding of how miRNAs drive the activity of immune cells, and how their modulation in vivo opens new avenues for diagnostic and therapeutic interventions in multiple diseases, from immunodeficiency to cancer. Recent contributions from our laboratory and other groups to novel formulations for miRNA mimetics are further discussed. 
proteins. Ago variants bind to a "guide" RNA strand that becomes unwound from the original double-stranded miRNA structure [1] . Interactions occur in such a manner that the "seed" region of this ssRNA has its Watson-and-Crick base edges exposed to complementary sequences that are typically found in the 3' untranslated region of target mRNAs [2] . Translation of hundreds of target genes can therefore be finely modulated by a single miRNA via mRNA degradation or translational repression, which (directly and indirectly) has dramatic effects in the acquisition of specific phenotypes in multiple cell types. transplant rejection [28] . Although the biological effects of these changes are unclear, the levels of both miR-142-3p and miR-142-5p are dramatically decreased in TCR-activated naïve CD8 T cells, but their expression becomes partially restored in memory lymphocytes [21] . Taken together, these results point to a role for miR-142 in promoting T cell quiescence, but more mechanistic studies are needed to clarify its complicated immunobiology. miR-223 is another miRNA that is selectively expressed in neutrophils and macrophages. Manipulation of miR-223 levels profoundly affects hematopoiesis [29] , but understanding its functional role has been complicated due to conflicting results in different experimental systems. It was initially thought that miR-223 promotes the differentiation of myeloid progenitors into granulocytes, based on ectopic expression studies in human leukemic cell lines [30] . However, miR-223 knockout mice have increased counts of granulocyte progenitors in the bone marrow and hypermature neutrophils in the circulation [31] . Further studies unveiled an elegant mechanism, whereby C/EBPα and NFI-A compete for binding to the miR-223 promoter.
During differentiation, C/EBPα replaces NFI-A, leading to the upregulation of miR-223, which in turn silences NFI-A [32, 33] . Thus, role in the development, survival and/or activity of many immune cells, relatively little is known about the functions of miR-142. It has been recently reported that, along with miR-29a, miR-142-3p directly silences the cyclin T2 gene, preventing the release of hypophosphorylated retinoblastoma and therefore promoting monocytic differentiation [22] . Correspondingly, a decrease in miR-142-3p levels is observed in blasts from acute myeloid leukemia [22, 23] , while miR-142-3p is translocated (fused with c-myc) in human B cell malignancy [24] .
In physiological responses in lineage-committed immune cells, miR-142-3p controls IL-6 production by LPS-stimulated dendritic cells (DCs), and dampening miR-142-3p activity reduces endotoxin-induced mortality [25] . miR-142-3p regulates the production of cAMP by targeting adenylyl cyclase 9 in regulatory T cells, thus mitigating their suppressor activity [26] . Further supporting a role for miR-142-3p in regulating T cell activity, CD4 T cells in patients with systemic lupus erythematosus show reduced expression of both (miR-142-3p/5p) strands, which promotes T cell activation and eventually leads to B cell hyperstimulation [27] . In contrast, miR-142-5p is overexpressed in peripheral blood in patients undergoing acute when released from damaged cells do not appear to up-regulate miR-155, but alter the expression of other miRNAs such as miR34c and miR-214 [48] , suggesting that a complex and fine-tuned network of miRNAs links inflammation and adaptive immunity. miR-146 is another miRNA involved with TLR signaling [49] , and is up-regulated in macrophages and DCs upon NF-κB nuclear translocation [50] . However, unlike miR-155, miR-146a inhibits NF−κB signaling, thus acting as an anti-inflammatory mediator. Consistent with a role as an inhibitor of excessive inflammation, miR146a is significantly decreased in leukocytes from systemic lupus erythematosus patients [51] . Furthermore, miR-146a plays a negative regulatory role in the development of myeloid cells, so that mice deficient in miR-146a display an excessive proliferation of leukocytes of the myeloid lineage [52] .
These effects appear to result from the up-regulation of the M-CSF receptor, although CSFR1 is not a direct target of miR146a [52] .
Of note, miRNAs that regulate the function of myeloid leukocytes are particularly relevant for therapeutic targeting, due to the spontaneous endocytic activity of these leukocytes, which enables systemic or local delivery of RNA mimetics in the form of micro-or nano-particles. miRNAs are critical for the function of lymphocytes.
Among the miRNAs that are critical for the development of the T cell compartment, perhaps the most investigated is miR-181.
Increasing miR-181a expression in mature T cells augments their sensitivity to peptide antigens and prevents the abrogation of cytotoxic function by downregulating multiple phosphatases, thus increasing the accumulation of specific phosphorylated intermediates and enhancing the cells' responses to T cell receptor signaling [5] . miR-181a targets include the dual specificity protein phosphatase DUSP6, and it has been recently proposed that a decline in miR-181a expression with age impairs TCR sensitivity by enhancing DUSP6 activity [53] . In addition, miR-181a promotes the deletion of particular clones with moderate affinity by modulating the threshold of TCR activation during thymic selection [54] .
Independent of its effects on hematopoietic development, the overall effects of miR-181 (e.g., activation vs. unresponsiveness) on mature, peripheral effector T cells are less clear. Functional miRNAs may not be absolutely required for the initial activation of effector T cells, although they are essential for their survival and functions [55] . In CD8 T cells, a limited set of miRNAs (miR-16, miR-21, miR-142-3p, miR-142-5p, miR-150, miR-15b and let-7f) are expressed at significantly higher levels at all stages of activation/differentiation, and, together, they account for ~60% of all miRNAs [21] . With the exception of miR-21, all of these miRNAs are significantly down-regulated upon TCR-mediated T cell activation, and their expression levels are restored back to intermediate levels when these stimulated T cells acquire a memory phenotype [21] . In contrast, miR-21, a major inhibitor of Th1 polarization that targets IL12 and IFN-γ [56] are selectively expressed by neutrophils [36] , while miR-378 is only expressed in monocytes [37] . 
miR-155 in particular is up-regulated in macrophages and
DCs in response to endotoxin [6] , TNFα [38] , or a synergistic cocktail of CD40 and TLR3 agonists [39, 40] . All these signals elicit DC activation and promote effective antigen presentation to T cells. miR-155 is also the only miRNA substantially upregulated by primary macrophages stimulated with a TLR3 agonist plus interferon-beta [6, 41] . Interestingly, DCs matured in the absence of miR-155 can express MHC-II and costimulatory molecules at levels comparable to those seen in identically treated matured wild-type DCs, but miR-155-deficient DCs fail to activate T cells, consistent with defective antigen presentation [5] . Correspondingly, mice that are deficient for miR-155 are also severely immunodeficient [6, 42] . As commented below, we have also demonstrated that supplementing miR-155 in (miR-155 low ) tumor-associated regulatory DCs [39] induces genome-wide transcriptional changes that transform them from an immunosuppressive to an immunostimulatory cell type [39] . Direct targets of miR-155 include immunosuppressive PU.1 [43] , SOCS1 [44] , CD200 [39] , and C/epb-β [39] . C/ epb-β, in conjunction with multiple mediators of transforming growth factor-beta (Tgf-β) signaling pathway (e.g., Tgf-β1, Smad1,Smad6 and Smad7 [46] ) drives immunosuppression in cancer-bearing hosts by promoting aberrant myelopoiesis [45] .
Furthermore, Ccl22, which recruits regulatory T cells to the tumor microenvironment [47] , is also down-regulated in the presence of enhanced miR-155 activity [39] . miR-155 is therefore the paradigm of a stimulatory "immunomiR," and perhaps the most show higher expression of Bim, which promotes apoptosis and subsequently inhibits B cell development at the pro-B to pre-B transition [64] . Correspondingly, transgenic mice with increased expression of miR-17∼92 develop lymphoproliferative disease and autoimmunity [65] . Dysregulation of miR-29 expression has also been associated with the pathogenesis of indolent B-CLL [66] .
In regards to miRNAs that regulate the function of myeloid leukocytes, miRNAs that govern T cell functions, in particular, could potentially be ectopically and stably supplemented with, for instance, viral vectors. These lymphocytes, with enhanced effector or regulatory functions, could then be adoptively transferred and exert their activity in vivo at, for instance, tumor locations or sites of inflammatory damage, respectively. in stimulated and memory lymphocytes, when compared to their naïve counterparts.
The four members of the miR-29 family regulate helper T cell differentiation by repressing multiple target genes [58] . miR-29 suppresses immune responses by directly targeting IFN-γ in NK cells and in CD4 and CD8 T lymphocytes [57] . In addition, the transcription factors T-bet and Eomes, which also induce IFN-γ, are regulated by miR-29. Thus, miR-29 regulates helper T cell differentiation by repressing multiple target genes .
As a paradigmatic immunostimulatory miRNA, miR-155 is also required for the function of T lymphocytes [6] . This, combined with the inability of miR-155-deficient DCs to activate T cells, contributes to explain the severe immunodeficiency observed in miR-155 knockout mice [6, 42] . miR-155 is required for T helper cell differentiation and, subsequently, an optimal T cell-dependent antibody response [42] . In addition, miR-155-deficient T cells show impaired expansion in response to CD3/ CD28 activation and secrete less IFN-γ and IL-17 than their wildtype counterparts [59] . In contrast, miR-155-mediated silencing of SOCS1 not only enhances differentiation of Treg cells, but also induce the generation of Th17 cells [60] . Nevertheless, an overall activating role is supported by the fact that miR-155 promotes autoimmune inflammation by enhancing inflammatory T cell development [61] , while decreasing its expression ameliorates murine autoimmune encephalomyelitis [62] . and autoimmune conditions [7] . For instance, the contribution of excessive miR-155 activity to the pathogenesis of systemic lupus erythematosus has been mechanistically demonstrated.
Figure 2. Peritoneal delivery of immunomiR-carrying polyplexes in ovarian cancer hosts elicits anti-tumor immunity. Intraperitoneally-injected nanoparticles encapsulating synthetic miR-155 are preferentially taken-up by regulatory phagocytes at ovarian cancer locations. Non-specific activation of TLR5 and TLR7, combined with silencing of immunosuppressive targets of endogenous immunomiRs elicits the activation of tumor-associated regulatory dendritic cells, transforming them from an immunosuppressive to an immunostimulatory cell type. In situ activated dendritic cells promote the expansion and function of anti-tumor T cells by effectively presenting tumor antigens engulfed in
Thus, miR-155 and, interestingly, miR-155*, co-operatively promote type I IFN production by human plasmacytoid DCs.
In a different setting of deleterious immunity(acute graftversus-host disease), as expected, miR-155 expression was up-regulated in T cells, in both mice and humans [86] . In addition, mice receiving miR-155-deficient donor lymphocytes had markedly reduced lethal acute graft-versus-host disease.
Most importantly, down-regulating miR-155 expression with antagomiRs decreased the severity of rejection and increased survival in experimental models. miR-155 therefore emerges as a target for therapeutic intervention also in transplantation, in this case through systemic delivery of antagonists.
In addition, several studies have reported the potential of miRNA changes in peripheral blood cells and allograft biopsies as biomarkers of failure in solid organ transplantation [28, 87] .
Besides the recurrent involvement of miR-155, hematopoieticspecific miRNAs (miR-142-5p and miR-223) were found by Anglicheau and colleagues to be overexpressed in both biopsies and peripheral leukocytes, although phytohaemagglutinin activation appears to decrease miR-223 expression [28] .
However, Sui and colleagues reported a very different set of differently expressed miRNAs in acute rejection after renal transplantation, which includes preferential up-regulation of miR-125a and miR-629, and preferential down-regulation of miR-324-3p and miR-611 [87] .
Role of miRNAs during HIV infection
As stated above, miRNAs play critical roles in regulating several developmental, physiological and pathological processes that involve different cellular subsets of the immune system. Thus, it is not surprising that these small RNAs could also participate miRNAs in anti-tumor immunity: The role of miR-155. Tumor-associated myeloid cells (mostly macrophages and regulatory DCs) typically express very low levels of miR-155. Correspondingly, they promote tolerance rather than eliciting protective immunity after phagocytosing tumor antigens [40, [77] [78] [79] [80] [81] . However, the antigen-processing capacity of these leukocytes can be promoted in vivo and in situ, simply by supplementing miR-155 in an accessible microenvironment such as the peritoneal cavity (e.g., in ovarian cancer) [39] .
Enhancing miR-155 activity resulted in down-regulation of multiple immunosuppressive genes, including SOCS1, PU.1, TGF-β and Cebp-β, which transformed tumor DCs from an immunosuppressive to an immunostimulatory cell type [39] .
Non-viral miR-155 delivery therefore emerges as a transient, safe and effective intervention that is ready for clinical testing.
It is important to note, however, that high levels of miR-155 expression has been associated with enhanced malignant potential. miR-155 is overexpressed in lymphomas and acute myeloid leukemia [82] , and stable overexpression of miR-155 in hematopoietic progenitors causes a myeloproliferative disorder [83] . In addition, constitutive (sustained) overexpression of miR-155 in the B cell lineage induces pre-B cell proliferation and promotes B cell malignancies [84] . Nevertheless [88] , suggesting that cellular miRNAs could directly target HIV transcripts to modulate the infectious life cycle. Functional experiments later confirmed that HIV mRNAs interact with the RNA induced silencing complex (RISC) and that disrupting cellular P body structures enhances HIV viral production and infectivity [89] . Specifically, miR-29a expressed by T cells is capable of repressing HIV replication by targeting the viral 3'UTR [88] . In addition, it has been reported that miR-29 family members can directly target HIV nef in order to inhibit viral replication [90] . Interestingly, the miR-29 family has recently been shown to regulate the production of interferon gamma in T cells by directly targeting the Tbx21 and Ifng genes [58] , indicating that miR-29 could also participate during the course of HIV infection by altering the proportions of circulating or tissue-specific Th1, Whatever the reasons are, the introduction of an internal bulge is critical for the functionality of miRNA mimicking sequences, and should be considered for future applications.
Besides supplementing miRNA activity, nucleic acids can be delivered in vivo and in vitro for specific silencing of overexpressed endogenous miRNAs in certain pathological conditions [103] . Chemically engineered oligonucleotides, termed 'antagomiRs', have been specifically optimized for this use, and proven to be effective upon intravenous administration. Therefore, the same platform used for augmenting the expression of selected miRNAs could be theoretically used to silence miRNAs with opposite activities, thus providing alternative tools for therapeutic interventions. Ectopic expression of "sponges" -tandem repetition of transcribed complementary sequences that "soak up" endogenous miRNAs [104] -can be stably achieved ex vivo in cells such as lymphocytes, which could then be adoptively transferred.
In conclusion, multiple viral and non-viral approaches are therefore available for in vivo modulation of miRNAs in immune cells, and therefore for immunotherapeutic interventions that should be both effective and mechanistically informative.
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This work was supported by NCI Grants CA157664 and CA124515, and by DoD grant OC100059. much more feasible approach, which also results in dramatic therapeutic effects [39] .
In this context, tumors that are reachable for intratumoral administration, or diseases such as ovarian cancer, which are accessible through intraperitoneal injection, are ideal for modulation of miRNA expression. While increasing or diminishing the expression of crucial miRNAs in other inflammatory and autoimmune conditions is also feasible, RNA delivery typically results in activation of multiple TLRs and other immune sensors, which will boost additional responses in a non-specific manner independently of sequence specificity [39, 76] . It should be noted, however, that DNA (not RNA)-carrying, PEI-based nanocomplexes were also recently found to induce a rapid (and non-specific) increase in type I Interferons (IFNs) when they were, as expected, selectively taken-up by phagocytes in vivo [98] . However, the authors propose that IFN type I receptor signaling eventually lead to IDO-mediated Treg activation and, correspondingly, regulatory outcomes. Because we have shown opposite (immunostimulatory) non-specific effects upon delivery of PEI-RNA polyplexes, it is likely that the systemic effects depend on target cells, which vary with different pathological conditions.
The same platform could be therefore theoretically used to deliver antagomiRs or to supplement inhibitory miRNAs in autoimmunity and transplantation, but more mechanistic studies are needed. 
